Tharimmune Stock Investor Sentiment

THAR Stock   1.41  0.28  16.57%   
Slightly above 62% of Tharimmune's investor base is looking to short. The analysis of the overall investor sentiment regarding Tharimmune suggests that many traders are alarmed. Tharimmune's investing sentiment overview a quick insight into current market opportunities from investing in Tharimmune. Many technical investors use Tharimmune stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
  
few days ago at thelincolnianonline.com         
Critical Survey Phio Pharmaceuticals vs. Tharimmune
news
over two weeks ago at thelincolnianonline.com         
Tharimmune Trading Up 3 percent Should You Buy?
news
over three weeks ago at finance.yahoo.com         
Tharimmune to Present at the Microcap Conference 2025
Yahoo News
over three weeks ago at news.google.com         
Tharimmune to Present at Microcap Conference 2025, Showcase Growth Strategy - StockTitan
Google News at Macroaxis
over a month ago at www.macroaxis.com         
Acquisition by Appajosyula Sireesh of 52875 shares of Tharimmune at 1.93 subject to Rule 16b-3
Macroaxis News
over two months ago at news.google.com         
tharimmune CEO Randy Milby buys shares worth 9,752 - Investing.com
Google News at Macroaxis
over two months ago at www.macroaxis.com         
Acquisition by Milby Randy of 4600 shares of Tharimmune at 2.12 subject to Rule 16b-3
Macroaxis News
over two months ago at finance.yahoo.com         
Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Assoc...
Yahoo News
over two months ago at news.google.com         
Tharimmune announces 2.02M private placement shares up - MSN
Google News at Macroaxis
over two months ago at thelincolnianonline.com         
Tharimmune, Inc. Announces 2.02 Million Private Placement for Clinical Development PurposesWashingto...
news
over two months ago at investing.com         
Rodman Renshaw sets price target on Tharimmune shares, rating Buy
Investing News at Macroaxis
over two months ago at finance.yahoo.com         
Tharimmune Announces 2.02 Million Private Placement to Advance Development Programs
Yahoo News
over two months ago at newswire.com         
Tharimmune Announces 2.02 Million Private Placement to Advance Development Programs
news
over three months ago at news.google.com         
Tharimmune Abandons Acquisition of Intract Pharma - MarketWatch
Google News at Macroaxis
over three months ago at www.macroaxis.com         
Insider Trading
Macroaxis News
Far too much social signal, news, headlines, and media speculation about Tharimmune that are available to investors today. That information is available publicly through Tharimmune media outlets and privately through word of mouth or via Tharimmune internal channels. However, regardless of the origin, that massive amount of Tharimmune data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Tharimmune news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Tharimmune relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Tharimmune's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Tharimmune alpha.

Tharimmune Performance against Dow Jones

 Price Growth (%)  
       Timeline  

Additional Tools for Tharimmune Stock Analysis

When running Tharimmune's price analysis, check to measure Tharimmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tharimmune is operating at the current time. Most of Tharimmune's value examination focuses on studying past and present price action to predict the probability of Tharimmune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tharimmune's price. Additionally, you may evaluate how the addition of Tharimmune to your portfolios can decrease your overall portfolio volatility.